APA aipamena

Bushnell, D. L., Madsen, M. T., O’cdorisio, T., Menda, Y., Muzahir, S., Ryan, R., & O’dorisio, M. S. (2014). Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res.

Chicago Style aipamena

Bushnell, David L., Mark T. Madsen, Thomas O’cdorisio, Yusuf Menda, Saima Muzahir, Randi Ryan, and M Sue O’dorisio. "Feasibility and Advantage of Adding (131)I-MIBG to (90)Y-DOTATOC for Treatment of Patients With Advanced Stage Neuroendocrine Tumors." EJNMMI Res 2014.

MLA aipamena

Bushnell, David L., et al. "Feasibility and Advantage of Adding (131)I-MIBG to (90)Y-DOTATOC for Treatment of Patients With Advanced Stage Neuroendocrine Tumors." EJNMMI Res 2014.